|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:1995
gptkb:FDA
|
|
gptkbp:clinical_trial
|
ongoing
|
|
gptkbp:community_health
|
gptkb:significant
|
|
gptkbp:contains
|
live attenuated virus
|
|
gptkbp:contraindication
|
pregnant women
immunocompromised individuals
|
|
gptkbp:cost_effectiveness
|
favorable
|
|
gptkbp:developed_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:diseases
|
gptkb:varicella
shingles
|
|
gptkbp:dosage_form
|
not routinely required
one dose for children
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
live attenuated varicella-zoster virus
|
|
gptkbp:indication
|
chickenpox vaccination
|
|
gptkbp:is_effective_against
|
over 90%
|
|
gptkbp:is_recommended_for
|
gptkb:children
|
|
gptkbp:is_vulnerable_to
|
high
global
important
increasing
live attenuated vaccine
addressed
second dose at 4-6 years
recommended at 12-15 months
|
|
gptkbp:market
|
conducted
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
induces immunity
|
|
gptkbp:recommendation
|
gptkb:CDC
gptkb:WHO
|
|
gptkbp:research_focus
|
long-term immunity
vaccine efficacy
safety in special populations
|
|
gptkbp:safety_features
|
well-studied
|
|
gptkbp:side_effect
|
rare
fever
mild rash
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:trade
|
gptkb:Varivax
|
|
gptkbp:used_for
|
prevention of chickenpox
|
|
gptkbp:bfsParent
|
gptkb:Zoster_vaccine
|
|
gptkbp:bfsLayer
|
6
|